Loading
Rock425 is an experimental immunotoxin from Rock Immune that carries a disabled diphtheria toxin to malignant T cells. It is being developed for cutaneous T-cell lymphoma and has not yet been tested in people.
Rock425 (CCR4-IL2 IT) is Rock Immune's lead candidate: a genetically engineered protein containing an anti-human CCR4 scFv and human IL-2 fused to truncated diphtheria toxin, expressed in the company's diphtheria toxin-resistant Pichia pastoris system. Rock Immune reports preclinical efficacy in a mouse model of human cutaneous T-cell lymphoma. No registered trial was found.
An anti-CCR4 single-chain antibody fragment and human IL-2 fused to a truncated diphtheria toxin, so that the toxin is carried into cells bearing CCR4 or the IL-2 receptor, as described by Rock Immune. Connects to CCR4.
1.Rock425's antibody arm binds CCR4 on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Rock425" OR ABSTRACT:"Rock425" OR TITLE:"CCR4-IL2 IT" OR ABSTRACT:"CCR4-IL2 IT" OR TITLE:"CCR4-IL2 bispecific immunotoxin" OR ABSTRACT:"CCR4-IL2 bispecific immunotoxin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rock425, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/